FIGO 2023 staging system predicts not only survival outcome but also recurrence pattern in corpus-confined endometrial cancer patients
Objective: Approximately 10–15 % of endometrial cancer patients with tumors confined to the uterus (FIGO 2009 stage I) demonstrate recurrence and the oncologic outcomes are highly related to recurrence patterns. This study aimed to verify whether the FIGO 2023 staging system could discriminate outco...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Taiwanese Journal of Obstetrics & Gynecology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1028455924002808 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553903166947328 |
|---|---|
| author | Hua-Hsi Wu Hung-Tse Chou Shih-Yao Lin Chiung-Ru Lai Yi-Jen Chen |
| author_facet | Hua-Hsi Wu Hung-Tse Chou Shih-Yao Lin Chiung-Ru Lai Yi-Jen Chen |
| author_sort | Hua-Hsi Wu |
| collection | DOAJ |
| description | Objective: Approximately 10–15 % of endometrial cancer patients with tumors confined to the uterus (FIGO 2009 stage I) demonstrate recurrence and the oncologic outcomes are highly related to recurrence patterns. This study aimed to verify whether the FIGO 2023 staging system could discriminate outcomes. Materials and methods: Between January 2010 and March 2019, 536 FIGO 2009 stage I patients were eligible for this retrospective cohort study. Patient characteristics and clinicopathological data were retrieved from electronic medical records. The patients were reclassified according to the FIGO 2023 staging criteria. Oncological outcomes included the recurrence rate, recurrence pattern, and overall survival. Results: Among the 536 eligible patients, the (sub)stage migration rate was 23.5 % from the FIGO 2009 to the FIGO 2023 stage system. FIGO 2023 staging system resulted in (sub)stage up-migration, mostly owing to aggressive histological types. A higher recurrence rate was detected in the FIGO 2023 stage II patients (12.3 %) compared to the stage I patients (6.9 %). In comparison to the FIGO 2023 stage I patients, the stage II patients had a higher distant recurrence rate (8.8 % vs. 2.6 %) and poorer overall survival (38.0 vs 69.0 months, p = 0.02). Conclusion: Patients who are upstaged are prone to worse oncological outcomes, including distant recurrence and mortality. Therefore, comprehensive adjuvant treatment strategies based on each FIGO 2023 substage are imperative. |
| format | Article |
| id | doaj-art-8bcf84fa65c94f439aab25f16d78b37d |
| institution | Kabale University |
| issn | 1028-4559 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Taiwanese Journal of Obstetrics & Gynecology |
| spelling | doaj-art-8bcf84fa65c94f439aab25f16d78b37d2025-01-09T06:12:50ZengElsevierTaiwanese Journal of Obstetrics & Gynecology1028-45592025-01-016417681FIGO 2023 staging system predicts not only survival outcome but also recurrence pattern in corpus-confined endometrial cancer patientsHua-Hsi Wu0Hung-Tse Chou1Shih-Yao Lin2Chiung-Ru Lai3Yi-Jen Chen4Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, TaiwanDepartment of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, TaiwanSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, TaiwanInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, TaiwanDepartment of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Corresponding author. Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, 201, Section 2, Shih-Pai Road, Taipei 11217, Taiwan.Objective: Approximately 10–15 % of endometrial cancer patients with tumors confined to the uterus (FIGO 2009 stage I) demonstrate recurrence and the oncologic outcomes are highly related to recurrence patterns. This study aimed to verify whether the FIGO 2023 staging system could discriminate outcomes. Materials and methods: Between January 2010 and March 2019, 536 FIGO 2009 stage I patients were eligible for this retrospective cohort study. Patient characteristics and clinicopathological data were retrieved from electronic medical records. The patients were reclassified according to the FIGO 2023 staging criteria. Oncological outcomes included the recurrence rate, recurrence pattern, and overall survival. Results: Among the 536 eligible patients, the (sub)stage migration rate was 23.5 % from the FIGO 2009 to the FIGO 2023 stage system. FIGO 2023 staging system resulted in (sub)stage up-migration, mostly owing to aggressive histological types. A higher recurrence rate was detected in the FIGO 2023 stage II patients (12.3 %) compared to the stage I patients (6.9 %). In comparison to the FIGO 2023 stage I patients, the stage II patients had a higher distant recurrence rate (8.8 % vs. 2.6 %) and poorer overall survival (38.0 vs 69.0 months, p = 0.02). Conclusion: Patients who are upstaged are prone to worse oncological outcomes, including distant recurrence and mortality. Therefore, comprehensive adjuvant treatment strategies based on each FIGO 2023 substage are imperative.http://www.sciencedirect.com/science/article/pii/S1028455924002808Endometrial cancerFIGO 2023 stageRecurrence pattern |
| spellingShingle | Hua-Hsi Wu Hung-Tse Chou Shih-Yao Lin Chiung-Ru Lai Yi-Jen Chen FIGO 2023 staging system predicts not only survival outcome but also recurrence pattern in corpus-confined endometrial cancer patients Taiwanese Journal of Obstetrics & Gynecology Endometrial cancer FIGO 2023 stage Recurrence pattern |
| title | FIGO 2023 staging system predicts not only survival outcome but also recurrence pattern in corpus-confined endometrial cancer patients |
| title_full | FIGO 2023 staging system predicts not only survival outcome but also recurrence pattern in corpus-confined endometrial cancer patients |
| title_fullStr | FIGO 2023 staging system predicts not only survival outcome but also recurrence pattern in corpus-confined endometrial cancer patients |
| title_full_unstemmed | FIGO 2023 staging system predicts not only survival outcome but also recurrence pattern in corpus-confined endometrial cancer patients |
| title_short | FIGO 2023 staging system predicts not only survival outcome but also recurrence pattern in corpus-confined endometrial cancer patients |
| title_sort | figo 2023 staging system predicts not only survival outcome but also recurrence pattern in corpus confined endometrial cancer patients |
| topic | Endometrial cancer FIGO 2023 stage Recurrence pattern |
| url | http://www.sciencedirect.com/science/article/pii/S1028455924002808 |
| work_keys_str_mv | AT huahsiwu figo2023stagingsystempredictsnotonlysurvivaloutcomebutalsorecurrencepatternincorpusconfinedendometrialcancerpatients AT hungtsechou figo2023stagingsystempredictsnotonlysurvivaloutcomebutalsorecurrencepatternincorpusconfinedendometrialcancerpatients AT shihyaolin figo2023stagingsystempredictsnotonlysurvivaloutcomebutalsorecurrencepatternincorpusconfinedendometrialcancerpatients AT chiungrulai figo2023stagingsystempredictsnotonlysurvivaloutcomebutalsorecurrencepatternincorpusconfinedendometrialcancerpatients AT yijenchen figo2023stagingsystempredictsnotonlysurvivaloutcomebutalsorecurrencepatternincorpusconfinedendometrialcancerpatients |